The US Food and Drug
Administration has approved
Bayer’s Adempas (riociguat) to
treat adults with two forms of
pulmonary hypertension, following
strong support from an FDA expert
panel (PD 08 Aug).
The FDA reviewed Adempas
under its priority review program,
which provides for an expedited
six-month review of drugs that may
offer major advances in treatment.
Adempas is not yet approved by
the TGA for marketing in Australia.The above article was sent to subscribers in Pharmacy Daily's issue from 10 Oct 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 10 Oct 13
NEW data from the Australian Institute of Health and Welfare has revealed around 43% (or 8.5 million) of Australians aged 16-85 have experienced a mental disorder at some point in their lives.
THE Pharmacy Guild of Australia has formally expressed its concerns regarding the potential merger between Sigma and Chemist Warehouse (PD 07 Dec 2023) to the Australian Competition and Consumer Commission (ACCC).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.